Elsevier

Life Sciences

Volume 66, Issue 3, 10 December 1999, Pages 257-264
Life Sciences

Supraspinal and spinal effects of [Phe1Ψ(CH2-NH)Gly2]-nociceptin(1–13)-NH2 on nociception in the rat

https://doi.org/10.1016/S0024-3205(99)00588-3Get rights and content

Abstract

A new derivative of the neuropeptide nociceptin (NC) has recently been developed. This molecule, the pseudopeptide [Phe1Ψ(CH2-NH)Gly2]-nociceptin(1–13)-NH2 was found to antagonize NC inhibitory effects in peripheral smooth muscle preparations in vitro. However, contrasting results have appeared as regards its pharmacodynamic profile in the CNS. Here, we investigated the pseudopeptide effects, in vivo, on nociceptive responses in the rat. [Phe1Ψ(CH2-NH)Gly2]-nociceptin(1–13)-NH2 was administered intracerebroventricularly (i.c.v.) or intrathecally (i.t.) (alone or in combination with NC), and tail-flick latencies (TFL) to radiant heat were assessed. I.c.v. [Phe1Ψ(CH2-NH)Gly2]-nociceptin(1–13)-NH2 (1–10 nmol/rat) caused a short-lasting decrease (5 min) of TFL and did not antagonize the threshold lowering effect of i.c.v. NC (1 nmol/rat). At the spinal level, the i.t. administration (0.2–10 nmol/rat) of [Phe1Ψ(CH2-NH)Gly2]-nociceptin(1–13)-NH2 produced a dose-dependent and long-lasting antinociceptive effect that was not modified by the administration of a high dose (30 nmol/rat i.t.) of the opioid antagonist naloxone. The i.t. co-administration of the pseudopeptide (10 nmol/rat) did not block the antinociceptive effect of i.t. NC (10 nmol/rat). These data indicate that the pseudopeptide behaves as an NC agonist at supraspinal and spinal levels in the rat tail-flick test of nociception. These different profiles in the periphery and the CNS could suggest differences between central and peripheral NC receptor/s and provide a basis for further development of antagonist molecules suitable for their characterization.

References (36)

  • J.-C Meunier

    Eur. J. Pharmacol.

    (1997)
  • G Henderson et al.

    Trends Pharmacol. Sci.

    (1997)
  • T Darland et al.

    Trends Neurosci.

    (1998)
  • J.L Butour et al.

    Eur. J. Pharmacol.

    (1998)
  • I.S Xu et al.

    Neurosci. Lett.

    (1998)
  • S Spampinato et al.

    Eur. J. Pharmacol.

    (1985)
  • M.A King et al.

    Neurosci. Lett.

    (1997)
  • J.S Mogil et al.

    Neurosci. Lett.

    (1996)
  • J.S Mogil et al.

    Neuroscience

    (1996)
  • F Noble et al.

    FEBS Lett.

    (1997)
  • D.P Devine et al.

    Brain Res.

    (1996)
  • X Chu et al.

    Eur. J. Pharmacol.

    (1999)
  • J.P Mathis et al.

    Biochem. Biophys. Res. Commun.

    (1997)
  • I.D Adapa et al.

    Neuropeptides

    (1997)
  • W.P Halford et al.

    J. Neuroimmunol.

    (1995)
  • J.B Wang et al.

    FEBS Lett.

    (1994)
  • M.J Wick et al.

    Mol. Brain Res.

    (1995)
  • J.-C Meunier et al.

    Nature

    (1995)
  • Cited by (22)

    • Nociceptive behavior and central neuropeptidergic dysregulations in male and female mice of a Fabry disease animal model

      2021, Brain Research Bulletin
      Citation Excerpt :

      Moreover, the dynorphin - KOP receptor system contributes to the negative affective component of pain (Cahill et al., 2014; Malan et al., 2000; Palmisano et al., 2019). A role for the nociceptin/orphanin FQ - NOP receptor system in pain modulation has been ascertained (Candeletti et al., 1999; Kiguchi et al., 2016; Meunier et al., 1995; Palmisano et al., 2017). The ability of NOP antagonist JTC-801 to reverse anxiety- and pain-like behaviors has been recently reported (Zhang et al., 2015), thus suggesting a common target for comorbidity of stress disorder and pain.

    • Pharmacological Modulation of Endogenous Opioid Activity to Attenuate Neuropathic Pain in Rats

      2019, Journal of Pain
      Citation Excerpt :

      Importantly, a number of studies have indicated the absence of significant supraspinal effects of i.t. injectate, even 60 minutes following i.t. injection.1,29,38 The i.t. doses of MPP (10 nmol), YM298198 (25 nmol), fadrozole (2.5 nmol), and naloxone (25 nmol) were based on previous studies,8,11,18,35,44,46,47,62 in order to maintain parallelism of i.t. treatments used in the current report and its 2 antecedent studies.46,47 Mechanical allodynia was quantified by measuring paw withdrawal thresholds of both ipsilateral and contralateral hind paws in response to the application of von Frey hair, as described by Chaplan et al.10 In brief, rats were placed on a wire mesh surface covered by an inverted plastic cage and were allowed to habituate for 15 minutes.

    • Acute and subchronic antinociceptive effects of nociceptin/orphanin FQ receptor agonists infused by intrathecal route in rats

      2015, European Journal of Pharmacology
      Citation Excerpt :

      This result is not completely unexpected. In fact, the NOP partial agonist [F/G]N/OFQ(1–13)–NH2 that shares with UFP-113 the chemical modification at the Phe1-Gly2 peptide bond that reduces efficacy (Calo׳ et al., 2000) displayed full agonist activity when given spinally in the rat tail flick test (Candeletti et al., 2000, Wang et al., 1999). Doses higher than 0.3 nmol for UFP-112 and 1 nmol for UFP-113 induced disruption of motor coordination.

    View all citing articles on Scopus
    View full text